Name: Pacific Edge (PEB) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

PEB

Pharmaceuticals, Biotechnology & Life Sciences

Pacific Edge

Short interest: 0.09%; 0.00 pp 30d; as of 8 Oct 2026
Reported shorts: 1.1M
Shares on issue: 1.242B

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Pacific Edge

Pacific Edge is a global cancer diagnostics company focused on developing and commercializing bladder cancer diagnostic and prognostic tests. Their key product, Cxbladder, is a suite of non-invasive genomic urine tests used for risk stratification, rule-out, and surveillance of urothelial bladder cancer. The company operates directly in New Zealand, Australia, Singapore, and the United States, and through distributors in other regions.

Company profile →

Pacific Edge (ASX:PEB) has 0.09% of its shares on issue reported as short positions as of 8 Oct 2026, or about 1,063,942 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. PEB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads PEB today

Zanger BreakoutWatchScore 15rank 1503 of 1942
CAN SLIMWatchScore 15rank 946 of 1541
Minervini Trend TemplateWatchScore 32rank 506 of 1716
Crowded-Short BreakoutWatchScore 15rank 657 of 1502
Quality compoundersWatchScore 15rank 1008 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

PEB fundamentals

In the year to 31 Mar 2026, Pacific Edge (ASX:PEB) recorded revenue of NZ$11.5M and a net loss after tax of NZ$35.8M. A year earlier it recorded revenue of NZ$21.8M and a net loss after tax of NZ$29.9M. Year-on-year growth: revenue −47.4% (FY). Net margin −311.1%, return on equity −194.7% (FY). Figures are in NZD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →